SMAD-4 gene expression in human colorectal cancer: Comparison with some clinical and pathological parameters

Wosiak, Agnieszka; Wodziński, Damian; Kolasa, Marcin; Sałagacka-Kubiak, Aleksandra; Balcerczak, Ewa

doi:10.1016/j.prp.2016.10.013

Cited by 3 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with other studies that the loss of SMAD4 protein expression in human ovarian cancer, it was associated with a weakened DNA binding capacity in the downstream pathway [19]. However, there is also research in which there was no significant difference between the SMAD4 expression level and the clinical stage analysis parameters, which may be related to the small differences in the study population [22]. Tone et al [11] identified R361G mutation of SMAD4 in 37 cases of primary low-grade serous ovarian carcinoma.…”

Section: Discussionmentioning

confidence: 69%

Sequencing of SMAD4 somatic variation in patients with serous ovarian cancer

2020

EJGO

View full text Add to dashboard Cite

Objective: A previous study has indicated SMAD4 mutations identified in patients with serous ovarian cancer. The aim of study is to analyze the SMAD4 mutation in Chinese people with primary serous ovarian cancer and attempt to build the correlation between the genotype and clinical phenotype or parameters of clinical pathological; thus to explore the precise general theory for individual treatment of serous ovarian cancer. Materials and Methods: The authors collected 90 serous ovarian cancer cases with primary samples that were identified by pathologist. DNA was extracted from paraffin-embedded tumor tissues. The exon 2, 8, 9 and 11 of SMAD4 mutation hotspots were screened by Sanger sequencing. Results: The authors detected neither heterozygous mutations nor homozygous mutations in exon 2, 8, 9, and 11 of SMAD4 in 90 cases of serous ovarian cancer. However, they identified a single nucleotide polymorphism (SNP) (rs77389132) in the intron 2 regions and searched the ExAC website (http://exac.broadinstitute.org/) for the SNP at Chr18: 48573689 and allele is A/G. Conclusions: The mutational rate of exons 2, 8, 9, and 11 of SMAD4 in serous ovarian cancer may be rare in Chinese people with primary serous ovarian cancer. Therefore, Seeking SMAD4 mutation for ovarian cancer susceptible population and individual treatment still need further pursuing.

show abstract

Section: Discussionmentioning

confidence: 69%

Sequencing of SMAD4 somatic variation in patients with serous ovarian cancer

2020

EJGO

View full text Add to dashboard Cite

show abstract

“…In the majority of CRC and GC patients with microsatellite instability (MSI), inactivating mutations in the TGFBR2 gene were shown[ 53 ]. Mutations in Smad4, which have been identified in > 30% of CRC patients, have been said to disrupt TGF-β signaling[ 54 ].…”

Section: Targeting the Tgf-β Pathwaymentioning

confidence: 99%

Molecular-targeted therapy toward precision medicine for gastrointestinal caner: Current progress and challenges

Matsuoka¹,

Yashiro²

2021

WJGO

View full text Add to dashboard Cite

Gastrointestinal (GI) cancer remains the deadliest cancer in the world. The current standard treatment for GI cancer focuses on 5-fluorouracil-based chemotherapeutic regimens and surgery, and molecular-targeted therapy is expected to be a more effective and less toxic therapeutic strategy for GI cancer. There is well-established evidence for the use of epidermal growth factor receptor-targeted and vascular endothelial growth factor-targeted antibodies, which should routinely be incorporated into treatment strategies for GI cancer. Other potential therapeutic targets involve the PI3K/AKT pathway, tumor growth factor-β pathway, mesenchymal-epithelial transition pathway, WNT pathway, poly (ADP-ribose) polymerase, and immune checkpoints. Many clinical trials assessing the agents of targeted therapy are underway and have presented promising and thought-provoking results. With the development of molecular biology techniques, we can identify more targetable molecular alterations in larger patient populations with GI cancer. Targeting these molecules will allow us to reach the goal of precision medicine and improve the outcomes of patients with GI cancer.

show abstract

RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies

Giopanou

Pintzas

2020

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

SMAD-4 gene expression in human colorectal cancer: Comparison with some clinical and pathological parameters

Cited by 3 publications

References 31 publications

Sequencing of SMAD4 somatic variation in patients with serous ovarian cancer

Sequencing of SMAD4 somatic variation in patients with serous ovarian cancer

Molecular-targeted therapy toward precision medicine for gastrointestinal caner: Current progress and challenges

RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies

Contact Info

Product

Resources

About